Esophageal cancer — the utility of PET/CT in staging prior to chemoradiation

Authors: Adam Deja, Marcin Włodarczyk

DOI: 10.5603/rpor.96869

Article type: Research paper

Published online: 2023-08-10

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited.
Esophageal cancer — the utility of PET/CT in staging prior to chemoradiation

10.5603/rpor.96869

Adam Deja1, Marcin Włodarczyk2
1Radiotherapy Department, Greater Poland Cancer Center, Poznań, Poland
2Breast Surgical Oncology Department, Greater Poland Cancer Centre, Poznań, Poland

Corresponding author: Adam Deja, M.D., Greater Poland Cancer Center, Radiotherapy Department, ul. Garbary 15, Poznań 61–866, Poland: e-mail: adam.deja@wco.pl

Abstract

Background and purpose: Thorough staging plays a significant role in determining therapy modality in esophageal cancer patients. The aim of this study was to assess whether positron emission tomography/computed tomography (PET/CT) may be safely omitted in selected groups of patients.

Materials and methods: This retrospective analysis included 37 esophageal cancer patients recruited to chemoradiation by the Multidisciplinary Tumor Board (MTB) at the Greater Poland Cancer Center in 2021. Prior to radiotherapy planning every patient was referred to PET/CT to have the extent of their disease assessed.

Results: Among 37 patients PET/CT changed the staging status to metastatic (M1) in six cases (3 planoepithelial and 3 adenocarcinomas). In all those cases but one (1 patient with supraclavicular node metastasis finally received chemoradiation) confirmation of distant metastases excluded patients from radical treatment. Interestingly, in the PET/CT distant positive group 3 patients were initially staged as locally advanced (without nodal involvement). The other 3 were initially identified as at least N2 in tomography.

Conclusion: Results of this report allowed the conclusion that PET/CT plays a key role in esophageal cancer patients considered for radical chemoradiation; therefore, it remains a necessary tool to exclude metastatic disease in both main pathology types. Since the delayed time for PET/CT scan in esophageal cancer patients planned to chemoradiation may negatively influence treatment results, the data should be alarming for national health provider.
Key words: esophageal cancer; radiotherapy; chemoradiation; PET/CT

Introduction

Definitive or preoperative chemoradiation remains the state of art treatment modality in most patients with locally or locoregionally advanced esophageal cancer [1–5]. Prior to radical treatment patients should undergo proper pre-treatment staging. This includes endoscopy with biopsy, blood tests, contrasted CT of abdomen and chest. When radical treatment is considered then 18-FDG-positron emission tomography (PET/CT) is recommended to confirm the presence or absence of distant metastases [6]. Due to restricted availability of PET/CT facilities, referral to PET/CT examination may lead to treatment delay [7].

The aim of this retrospective study was to evaluate the utility of PET/CT (18-FDG-positron emission tomography/computed tomography) in patients with locally or locoregionally advanced esophageal cancer who are being considered for radical chemoradiation.

The findings of the study aim to provide evidence supporting the necessity of PET/CT in the staging and treatment planning process for esophageal cancer patients undergoing definitive chemoradiation.

Material and methods

The study included 37 consecutive esophageal cancer patients who were recruited for chemoradiation by the Multidisciplinary Tumor Board (MTB) at the Greater Poland Cancer Center (Wielkopolskie Centrum Onkologii, WCO) in 2021.

The inclusion criteria were as follows: patients with esophageal cancer who did not have distant metastases detected at the time of MTB and Eastern Cooperative Oncology Group (ECOG) Performance Status was at least ECOG-2. Very early lesions that were able to be managed through endoscopic procedures or definitive surgery were excluded from the analysis. Out of the 37 patients, 24 were male and 13 were female, with an average age of 65. The performance status of the patients was classified as ECOG 0–2, indicating a range from fully active to being ambulatory but limited in physical activity. In terms of histology, squamous cell carcinoma was the dominant type, observed in 30 patients, while adenocarcinoma was present in 7 patients (Fig. 1).
The study period encompassed the year 2021, during which the patients were discussed by the MTB and referred to chemoradiation. Their data was analyzed retrospectively to assess the role of PET/CT in the staging and management of esophageal cancer patients undergoing chemoradiation.

**Pathology**

<table>
<thead>
<tr>
<th>Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCC</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
</tr>
</tbody>
</table>

![Pathology](image.jpg)

**Figure 1.** Tumor pathology proportion in the study. SCC — squamos cell carcinoma

Prior to radiotherapy planning every patient was referred to PET/CT to have the extent of their disease assessed. Staging was based on the American Joint Committee on Cancer (AJCC) Tumour–Node–Metastasis (TNM) Staging Classification for Carcinoma of the Esophagus and Esophagogastric Junction (8th ed., 2017). Cervical nodes metastases were considered distant in case of non-cervical primary tumor.

Radiotherapy was based on CT scan with PET/CT fusion to ensure proper tumor delineation. In certain cases the 4-D gating technique was implemented. The total dose in chemoradiation schedule ranged from 41.4 Gy to 66.4 Gy delivered in 5 fractions a week with weekly carboplatin/paclitaxel.

**Results**

Among 37 patients PET/CT changed the staging status to metastatic (M1) in six cases (3 planoepithelial and 3 adenocarcinomas). In all those cases but one (1 patient with supraclavicular node metastasis finally received chemoradiation) confirmation of distant metastases excluded patients from radical treatment. Interestingly, in the PET/CT distant positive group 3 patients were initially staged as locally advanced (without nodal involvement). The other 3 were initially identified as at least N2 in tomography. In the whole
cohort, based on conventional imaging, 20 out of 30 squamous cell carcinomas and 5 out of 7 adenocarcinomas showed nodal involvement.

Table 1. Pattern of disease dissemination in positron emission tomography/computed tomography (PET/CT) in patients with metastases (M+) included in the study

<table>
<thead>
<tr>
<th>Patient no</th>
<th>Pathology</th>
<th>CT-based TNM</th>
<th>PET/CT result</th>
<th>Final treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Planoepithelial</td>
<td>T2N2M0</td>
<td>Lung metastasis/second primary</td>
<td>Supportive care</td>
</tr>
<tr>
<td>2.</td>
<td>Planoepithelial</td>
<td>T2N0M0</td>
<td>Non-regional nodal metastasis</td>
<td>RTCT</td>
</tr>
<tr>
<td>3.</td>
<td>Planoepithelial</td>
<td>T2N0M0</td>
<td>Liver and bone mets</td>
<td>Radiotherapy</td>
</tr>
<tr>
<td>4.</td>
<td>Adenocarcinoma</td>
<td>T3N3M0</td>
<td>Liver and non-regional nodal mets</td>
<td>Systemic therapy, radiotherapy</td>
</tr>
<tr>
<td>5.</td>
<td>Adenocarcinoma</td>
<td>T2N0M0</td>
<td>Liver and bone mets</td>
<td>Radiotherapy</td>
</tr>
<tr>
<td>6.</td>
<td>Adenocarcinoma</td>
<td>T3N3M0</td>
<td>Non-regional nodal metastasis</td>
<td>Radiotherapy</td>
</tr>
</tbody>
</table>

RTCT — radiotherapy plus chemotherapy

Discussion

This study investigates the utility of PET in staging potentially curative esophageal carcinoma. Given the challenges associated with accessing PET/CT facilities in certain regions [7], it is worth discussing whether this diagnostic tool is necessary for all cases of esophageal cancer. Current guidelines recommend the use of PET/CT in the staging workup [8].

A systematic review conducted by van Westreenen et al. assessed the staging performance of FDG-PET in esophageal cancer [9]. Their study demonstrated the high sensitivity and specificity of FDG-PET in identifying both local and distant metastases. The findings
emphasized the superior performance of FDG-PET in detecting distant metastases, particularly in non-regional lymph nodes, liver, and bone. These results confirm the essential role of FDG-PET in accurately staging and excluding metastatic disease in esophageal cancer.

Flamen et al. investigated the utility of FDG-PET in staging patients with potentially operable esophageal carcinoma [10]. Their study evaluated the impact of FDG-PET on treatment decision-making, particularly in identifying patients suitable for surgery. The findings demonstrated that FDG-PET provided additional crucial information, leading to modifications in the management plans of a significant number of patients. FDG-PET contributed to the detection of distant metastases, resulting in the exclusion of patients from surgery and the initiation of alternative treatment strategies.

Our study reaffirms that PET/CT remains an indispensable diagnostic tool for excluding distant metastases. Its utility was evident across both squamous cell carcinoma and adenocarcinoma, with 10% of squamous cell carcinoma patients and 43% of adenocarcinoma patients identified as having metastases based on PET/CT findings. Although the pattern of distant metastases varied, commonly affected sites included the liver, bone, and non-regional lymph nodes. In one case, the presence of a lung tumor was suspected; however, due to complications related to a fistula, the patient did not receive radiotherapy, and pulmonary diagnostics were incomplete.

Notably, the locoregional advancement observed on contrast-enhanced CT did not consistently correlate with PET/CT results. The time interval between these diagnostic modalities may play a role in this disparity. In our study, the average delay from the baseline CT scan to PET/CT was 45 days, a significant duration that could potentially impact disease progression and worsen treatment prognosis.

Furthermore, disease confined solely to the esophagus, as identified by baseline CT without nodal involvement, did not guarantee the absence of distant metastases on PET/CT. This finding suggests that PET/CT should not be omitted even in cases of relatively less advanced tumors. While the utility of PET/CT in the diagnostic workup is unquestioned in both clinical practice and guidelines, its integration into radiotherapy planning remains uncertain. As the authors of the "systematic review on the role of FDG-PET/CT in tumor delineation and radiotherapy planning in patients with esophageal cancer" conclude [11], "it is not established as a standard and requires further investigation."
Conclusion

The study concludes that PET/CT is a crucial diagnostic tool in esophageal cancer patients undergoing radical chemoradiation. It plays a key role in excluding metastatic disease, allowing for appropriate treatment planning. The findings show that PET/CT changed the staging status to metastatic in six cases, leading to the exclusion of these patients from radical treatment.

The study suggests that PET/CT should not be omitted even in relatively less advanced tumors confined to the esophagus only. The study highlights the importance of timely access to PET/CT facilities, as the delay in obtaining scans may impact disease progression and treatment prognosis.

Ethical permission

Ethical approval was not necessary for the preparation of this article.

Conflicts of interest

Authors have no conflict of interest to declare.

Funding

This publication was prepared without any external source of funding.

References


